Result:Weak#Base effect
| Metric | Value (₹ Cr) | vs Q4 FY26 |
|---|---|---|
| Revenue | 0.18 | 98.4% |
| Total Income | 0.18 | 98.4% |
| Expenditure | 0.49 | 96.0% |
| PBT | -0.31 | 48.7% |
| Net Profit | -0.40 | 64.4% |
| OPM | -33.99% | 33.52pp |
| NPM | — | |
| EPS | 1.38 | 66.3% |
Deep pharma loss narrowed sharply YoY off a near-zero revenue base, so despite improved PAT the tiny/negligible top-line and continued negative margins keep this below-par.
Informational and educational content only. Not investment advice.